Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeucaLTS:0MJR 95 EV-to-EBITDA is 9.86 as of Aug. 21, 2026, which is 4% below its 10-year median of 10.24. GuruFocus rates LTS:0MJR with a GF Score™ of 95/100 and a GF Value™ of zł884.69. The stock has 5 warning signs investors should review. Among 98 Medical Distribution companies, Neuca ranks worse than 63.27% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Neuca's enterprise value is zł4,047 Mil.
Neuca's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was zł411 Mil. Therefore, Neuca's EV-to-EBITDA for today is 9.86.
The historical rank and industry rank for Neuca's EV-to-EBITDA or its related term are showing as below:
LTS:0MJR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.34 Med: 10.24 Max: 16.13
Current: 9.85
During the past 13 years, the highest EV-to-EBITDA of Neuca was 16.13. The lowest was 7.34. And the median was 10.24.
LTS:0MJR's EV-to-EBITDA is ranked worse than 63.27% of 98
companies
in the Medical Distribution industry
Industry Median: 8.405
vs LTS:0MJR: 9.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-21), Neuca's stock price is zł760.00.
Neuca's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was zł38.030. Therefore, Neuca's PE Ratio (TTM) for today is 19.98.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neuca's share price for today is zł760.00.
Neuca's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł38.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Neuca's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0MJR vs MCK, COR, CAH: EV-to-EBITDA Comparison
For the Medical Distribution subindustry, Neuca's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuca EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Neuca's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Neuca's EV-to-EBITDA falls into.
Neuca's current Enterprise Value is zł4,047 Mil.
Neuca's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł411 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuca (LTS:0MJR) has a EV-to-EBITDA of 9.86 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Neuca. This is near median its historical median of 10.24. Over the past decade, Neuca's EV-to-EBITDA has ranged from 7.34 to 16.13. According to the industry distribution chart, Neuca ranks #62 out of 98 companies in the Medical Distribution industry, placing it in the top 63.3%.
Is Neuca's EV-to-EBITDA too high?
Neuca's current EV-to-EBITDA of 9.86 is near median its 10-year median of 10.24. Over the past 10 years, this metric has ranged from a low of 7.34 to a high of 16.13. The Medical Distribution industry median EV-to-EBITDA is 8.41. Neuca's value of 9.86 is 17.3% above this industry median. Based on the distribution chart, Neuca ranks #62 out of 98 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Neuca has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Neuca's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Neuca ranks #62 out of 98 companies for EV-to-EBITDA. This places Neuca in the lower half of its industry. The industry median EV-to-EBITDA is 8.41. Neuca's value of 9.86 is 17.3% above this benchmark. Historically, Neuca's own EV-to-EBITDA has ranged from 7.34 to 16.13 over the past decade. While the company's 10-year median is 10.24 vs. the industry median of 8.41, Neuca has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.41, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuca's current EV-to-EBITDA of 9.86 is 17.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Neuca. For the Medical Distribution industry, the median EV-to-EBITDA is 8.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuca's current EV-to-EBITDA is 9.86, which is near median its own 10-year median of 10.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuca stock overvalued right now?
Neuca (LTS:0MJR) has a current EV-to-EBITDA of 9.86. The stock's GF Value™ is zł884.69, compared to a current price of zł760.00 — trading 14.1% below its estimated fair value. The current EV-to-EBITDA is 9.86, which is near median its 10-year median of 10.24 and 17.3% above the Medical Distribution industry median of 8.41. Neuca's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Neuca (LTS:0MJR), the current EV-to-EBITDA is 9.86 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuca (LTS:0MJR) Overvalued in 2026?
Based on GuruFocus' analysis, Neuca stock appears to be undervalued.
The current stock price of zł760.00 is trading 14.1% below its estimated GF Value™ of zł884.69.
Key valuation signals for LTS:0MJR:
EV-to-EBITDA: 9.86 (near median its 10-year median of 10.24)
GF Value™: zł884.69 vs. price of zł760.00 (14.1% below fair value)
Industry Position: 17.3% above the Medical Distribution median (#62 of 98)
No single metric tells the full story. See the LTS:0MJR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuca SA is a wholesale distributor of pharmaceuticals in Poland. The company's segment includes Pharmacy wholesale; Manufacture of pharmaceuticals; Outpatient medical care clinics; Clinical trials and Insurance activities. It generates maximum revenue from the Pharmacy wholesale segment.
95GF Score
Get the complete analysis for LTS:0MJR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0MJR has been successfully added to your 
